Skip to main content
SpringerLink
Log in

The Renin-Angiotensin System, Converting Enzyme Inhibition, and Antihypertensive Therapy

  • Chapter
Progress in Hormone Biochemistry and Pharmacology

Part of the book series: Progress in Hormone Biochemistry and Pharmacology ((PRHO,volume 1))

  • 51 Accesses

Abstract

In the past 80 years, the renin-angiotensin-aldosterone system, the kallikrein-kinin-prostaglandin system, and the role of the angiotensin- converting enzyme have been undergoing ever-increasing investigation in the pathogenesis of hypertension and in related cardiovascular disorders. Much insight has been obtained, but, controversial findings in some areas give further promise of even more biochemical and physiological, and pharmacological studies and analyses in animals and in man.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ondetti, M.A., Williams, N.J., Sabo, E.F., Pluščec, J., Weaver, E.R., and Kocy, O., Angiotensin-Converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis, Biochemistry, 10, 4033, 1971.

    PubMed  CAS  Google Scholar 

  2. Cheung, H.S. and Cushman, D.W., Inhibition of homogeneous angiotensin-convert-ing enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca, Biochem. Biophys. Acta, 293, 451, 1973.

    PubMed  CAS  Google Scholar 

  3. Ondetti, M.A., Rubin, B., and Cushman, D.W., Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents, Science, 196, 441, 1977.

    PubMed  CAS  Google Scholar 

  4. Laragh, J.H. and Sealey, J.E.,Therenin-angiotensin-aldosterone hormonal system and regulation of sodium, potassium and blood pressure homeostasis, in Handbook of Physiology, Sect. 8, Renal Physiology, Orloff, J. and Berliner, R.W., Eds., Amer. Physiol. Soc., Washington, D.C., 1973, 815.

    Google Scholar 

  5. Davis, J.O. and Freeman, R.H., Mechanisms regulating renin release, Physiol. Rev., 56, 1, 1976.

    PubMed  CAS  Google Scholar 

  6. Ganten, D. and Gross, F., Interference with the renin-angiotensin system and their effects on high blood pressure, in Handbook of Experimental Pharmacology, Vol. 39, Antihypertensive Agents, Gross, F., Ed., Springer-Verlag, Berlin, 1977, chap. 11.

    Google Scholar 

  7. Peach, M.J., Renin-angiotensin system: biochemistry and mechanisms of action, Physiol. Rev., 57,313, 1977.

    PubMed  CAS  Google Scholar 

  8. Vecsei, P., Hackenthal, E., and Ganten, D., The renin-angiotensin-aldosterone system, Klin. Wochenschr., 56 (Suppl. 1), 5, 1978.

    Google Scholar 

  9. Pisano, J.J. and Austen, K.F., Eds., Chemistry and biology of the kallikrein-kinin system in health and disease, U.S. Govt. Printing Office, Washington, D.C., DHEW Publication No. (NIH) 76-791, 1974, chap. 1-76.

    Google Scholar 

  10. Vane, J.R. and McGiff, J.C., Possible contributions of prostaglandins to the control of blood pressure, Circ. Res., 36/37, 1–68, 1975.

    Google Scholar 

  11. Carretero, O.A. and Scicli, A.G., The renal kallikrein-kinin system in human and in experimental hypertension, Klin. Vlochenschr., 56 (Suppl. 1), 113, 1978.

    Google Scholar 

  12. Dusting, G.J., Moncada, S., and Vane, J.R., Prostaglandins, their intermediates and precursors: cardiovascular actions and regulatory roles in normal and abnormal circulatory systems, Progr. Cardiovasc. Dis., 21, 405, 1979.

    CAS  Google Scholar 

  13. Nasjletti, A. and Malik, K.U., Relationships between the kallikrein-kinin and prostaglandin systems, Life Sci., 25, 99, 1979.

    PubMed  CAS  Google Scholar 

  14. Cushman, D.W. and Ondetti, M.A., Inhibitors of angiotensin-converting enzyme, Progr. Med. Chem., 17, in press, 1980.

    Google Scholar 

  15. Erdös, E.G., Angiotensin I converting enzyme, Circ. Res., 36, 247, 1975.

    PubMed  Google Scholar 

  16. Erdös, E.G., Commentary. The kinins, Biochem. Pharmacol., 25, 1563, 1976.

    PubMed  Google Scholar 

  17. Erdös, E.G., Conversion of angiotensin I to angiotensin II, Am. J. Med., 60, 749, 1976.

    PubMed  Google Scholar 

  18. Erdes, E.G., Ed., Handbook of Experimental Pharmacology, Vol. 25, Bradykinin, kallidin, and kallikrein, Springer-Verlag, Berlin, 1970, chap. 1-9.

    Google Scholar 

  19. Erdes, E.G., Ed., Handbook of Experimental Pharmacology, Vol. 25 Suppl., Bradykinin, kallidin, and kallikrein, Springer-Verlag, Berlin, 1979, chap. 1-17.

    Google Scholar 

  20. Page, I.H. and Bumpus, F.M., Eds., Handbook of Experimental Pharmacology, Vol. 37, Angiotensin, Springer-Verlag, Berlin, 1974, p. 1–519.

    Google Scholar 

  21. Ondetti, M.A. and Cushman, D.W., Inhibitors of the renin-angiotensin system, Annu. Rep. Med. Chem., 13, 82, 1978.

    CAS  Google Scholar 

  22. Cushman, D.W., Cheung, H.S., Sabo, E.F., Rubin, B., and Ondetti, M.A., Development of specific inhibitors of angiotensin I converting enzyme (kininase II), Fed. Proc, 38, 2778, 1979

    Google Scholar 

  23. Levinsky, N.G., The renal kallikrein-kinin system, Circ. Res., 44, 441, 1979.

    PubMed  CAS  Google Scholar 

  24. McGiff, J.C. and Wong, P.Y-K, Compartmentalization of prostaglandins and prostacyclin within the kidney: implications for renal function, Fed. Proc., 38, 89, 1979.

    PubMed  CAS  Google Scholar 

  25. Tigerstedt, R. and Bergman, P.G., Niere und Kreislauf, Skand. Arch. Physiol., 8, 223, 1898.

    Google Scholar 

  26. Goldblatt, H., Lynch, J., Hanzal, R.F., and Summerville, W.W., Studies on experimental hypertension. Production of persistent elevation of systolic blood pressure by means of renal ischemia, J. Exp. Med., 59, 347, 1934.

    PubMed  CAS  Google Scholar 

  27. Braun-Menéndez, E.J., Fasciolo, J.C, Lelou, L.F., and Mñnoz, J.M., La substancia hipertensora de la sangre del riñon isquemiado, Rev. Soc. Arg. Biol., 15, 420, 1939.

    Google Scholar 

  28. Page, I.H. and Helmer, O.M., A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin activator, J. Exp. Med., 71, 29, 1940.

    PubMed  CAS  Google Scholar 

  29. Braun-Menéndez, E.J. and Page, I.H., Suggested revision of nomenclature-angio-tensin, Science, 127, 242, 1958.

    PubMed  Google Scholar 

  30. Skeggs, L.T., Marsh, W.H., Kahn, J.R., and Shumway, N.P., The existence of two forms of hypertensin, J. Exp. Med., 99, 275, 1954.

    PubMed  CAS  Google Scholar 

  31. Lentz, K.E., Skeggs, L.T., Woods, K.R., Kahn, J.R., and Shumway, N.P., The amino acid composition of hypertensin II and its biochemical relationship to hypertension, J. Exp. Med., 104, 183, 1956.

    PubMed  CAS  Google Scholar 

  32. Elliott, D.F. and Peart, W.S., The amino acid sequence in a hypertensin, Biochem J., 65, 246, 1957.

    PubMed  CAS  Google Scholar 

  33. Skeggs, L.T., Lentz, K.E., Kehr, J.R., Shumway, N.P., and Woods, K.R., Amino acid sequence of hypertensin II, J. Exp. Med., 104, 193, 1956.

    PubMed  CAS  Google Scholar 

  34. Schwyzer, R., Iselin, B., Kappeler, H., Rinker, B., Rittel, W., and Zuber, H., Syntheses von Hypertensin-peptiden, Chimie (Aarau), 11, 335, 1957.

    CAS  Google Scholar 

  35. Bumpus, F.M., Schwarz, H., and Page, I.H., Synthesis and pharmacology of the octapeptide angiotensin, Science, 125, 886, 1957.

    PubMed  CAS  Google Scholar 

  36. Carpenter, C.C.J., Davis, J.O., and Ayers, C.R., Relation of renin, angiotensin II and experimental renal hypertension to aldosterone secretion, J. Clin. Invest., 40, 2026, 1961.

    PubMed  CAS  Google Scholar 

  37. Genest, J., Biron, P., Koiw, E., Nowaczynski, W., Chretein, M., and Boucher R., Adrenocortical hormones in human hypertension and their relation to angiotensin, Circ. Res., 9, 775, 1961.

    PubMed  CAS  Google Scholar 

  38. Gross, F., Renin und hypertensin, physiologische oder pathologische Wirkstoffe? Klin. Wochenschr., 36, 693, 1958.

    PubMed  CAS  Google Scholar 

  39. Laragh, J.H., The role of aldosterone in man: evidence for regulation of electrolyte balance and arterial pressure by renal-adrenal system which may be involved in malignant hypertension, J. Am. Med. Assoc., 174, 293, 1960.

    CAS  Google Scholar 

  40. Mulrow, P.J., Ganong, W.F., Cera, G., and Kuljian, A., Nature of aldosterone stimulating factors in dog kidneys, J. Clin. Invest., 41, 505, 1962.

    PubMed  CAS  Google Scholar 

  41. Ng, K.K.F. and Vane, J.R., Conversion of angiotensin I to angiotensin II, Nature, 216, 762, 1967.

    PubMed  CAS  Google Scholar 

  42. Blair-West, J.R., Coghlan, J.P., Denton, D.A., Funder, J.W., Scoggins, B.A. and Wright, R.D., The effect of the heptapeptide (2-8) and the hexapeptide (3-8) fragments of angiotensin II on aldosterone secretion, J. Clin. Endocrinol. Metab., 32, 575, 1971.

    PubMed  CAS  Google Scholar 

  43. Goodfriend, T.L. and Peach, M.J., Angiotensin III; (des-aspartic acid )-angio-tensin II. Evidence and speculation for its role as an important agonist in the renin-angiotensin system. Circ. Res., 36/37, 1–38, 1975..

    Google Scholar 

  44. McCaa, R.E., Aldosterone response to long term infusion of angiotensin II and angiotensin III in conscious dogs before and after dietary sodium restriction, Endocrinology, 103, 458, 1978.

    PubMed  CAS  Google Scholar 

  45. Werle, E., Discovery of the most important kallikreins and kallikrein inhibitors, in Handbook of Experimental Pharmacology, Vol. 25, Bradykinin, Kallidin and Kallikrein, Erdes, E.G., Ed., Springer-Verlag, Berlin, 1970, chap. 1.

    Google Scholar 

  46. Eisen, V. and Vogt, W., Plasma kininogenases and their activators, in Handbook of Experimental Pharmacology, Vol. 25, Bradykinin, Kallidin and Kallikrein, Erdos, E.G., Ed., Springer-Verlag, Berlin, 1970, chap. 3.

    Google Scholar 

  47. Webster, M.E., Kallikreins in glandular tissues; recommendations for nomenclature and units, in Handbook of Experimental Pharmacology, Vol. 25, Bradykinin, Kallidin and Kallikrein, Erdös, E.G., Ed., Springer-Verlag, Berlin, 1970, p. 131 and p. 659.

    Google Scholar 

  48. Rocha e Silva, M., Beraldo, W.T., and Rosenfeld, G., Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin, Am. J. Physiol., 156, 261, 1949.

    Google Scholar 

  49. Elliott, D.F., Horton, E.W., and Lewis, G.P., Actions of pure bradykinin, J. Physiol., 153, 473, 1960.

    PubMed  CAS  Google Scholar 

  50. Boissonnas, R.A., Guttman, S., and Jaquenod, P.A., Synthese de la L-arginyl-L-prolyl-L-prolyl-glycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phénylalanyl-L-arginine, un nonapeptide Drésentant les propriétés de la bradykinine, Helv. chem. Acta, 43, 1349, 1960.

    CAS  Google Scholar 

  51. Igic, R., Erdös, E.G., Yeh, H.S.J., Sorelic, K., and Nakajima, T., Angiotensin I converting enzyme of the lung, Cire. Res., 30/31, 11–51, 1972.

    Google Scholar 

  52. Ferreira, S.H., A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, Brit. J. Pharmacol., 24, 163, 1965.

    PubMed  CAS  Google Scholar 

  53. Bakhle, Y.S., Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung, Nature, 220, 919, 1968.

    PubMed  CAS  Google Scholar 

  54. Ferreira, S.H., Bartelt, D.C., and Greene, L.J., Isolation of bradykinin potentiating peptides from Bothrops jararaca venom, Biochemistry, 9, 2583, 1970.

    PubMed  CAS  Google Scholar 

  55. Ferreira, S.H., Greene, L.J., Alabaster, V.A., Bakhle, Y.S., and Vane, J.R., Activity of various fractions of bradykinin potentiating factor against angio-tensin-converting enzyme, Nature, 225, 379, 1970.

    PubMed  CAS  Google Scholar 

  56. Stewart, J.M., Ferreira, S.H., and Greene, L.J., Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II, Biochem. Pharmacol., 20, 1557, 1971.

    CAS  Google Scholar 

  57. Cushman, D.W. and Cheung, H.S., Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung, Biochem. Pharmacol., 20, 1637, 1971.

    CAS  Google Scholar 

  58. Engel, S.L., Schaeffer, T.R., Gold, B.I., and Rubin, B., Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bradykinin by synthetic peptides, Proc. Soc. Exp. Biol. Med., 140, 240, 1972.

    PubMed  CAS  Google Scholar 

  59. O’Keefe, E.H., Kotier, D.G., Waugh, M.H., and Rubin, B., Inhibition and augmentation by peptide SQ 20,881 of contractile effects of angiotensin I (AI) and of bradykinin (B), respectively, on excised smooth muscle, Fed. Proc., 31, 511, 1972.

    Google Scholar 

  60. Kato, H. and Suzuki, T., Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffii. Isolation of five bradykinin potentiators and the amino acid sequence of two of them, potentiators B and C, Biochemistry, 10, 972, 1971.

    PubMed  CAS  Google Scholar 

  61. Bakhle, Y.S., Inhibition of converting enzyme by venom peptides, in Hypertension, Genest, J. and Koiw, E., Eds., Springer-Verlag, Berlin, 1972, p. 541.

    Google Scholar 

  62. Greene, L.J., Camargo, A.C.M., Krieger, E.M., Stewart, J.M., and Ferreira, S.H., Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom, Circ. Res., 30/31, 11–62, 1972.

    Google Scholar 

  63. Engel, S.L., Schaeffer, T.R., Waugh, M.H., and Rubin, B., Effects of the nona-peptide SQ 20,881 on blood pressure of rats with experimental hypertension, Proc. Soc. Exp. Biol. Med., 143, 483, 1973.

    PubMed  CAS  Google Scholar 

  64. Muirhead, E.E., Brooks, B., and Arora, K.K., Prevention of malignant hypertension by the synthetic peptide SQ 20,881, Lab. Invest., 30, 129, 1974.

    CAS  Google Scholar 

  65. Collier, J.G., Robison, B.F., and Vane, J.R., Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide which inhibits converting enzyme, Lancet, 1, 72, 1973.

    PubMed  CAS  Google Scholar 

  66. Gavras, H., Brunner, H.R., Laragh, J.H., and Vukovich, R.A., An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N.Engl. J. Med., 291, 817, 1974.

    PubMed  CAS  Google Scholar 

  67. Johnson, J.G., Black, W.D., Vukovich, R.A., Hatch, F.E., Jr., Friedman, B.I., Blackwell, C.F., Shenouda, A., Share, L., Shade, R.E., Acchiardo, S.R., and Muirhead, E.E., Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme, Clin. Sci. Mol. Med., 48, 53s, 1975.

    Google Scholar 

  68. Case, D.B., Wallace, J.M., Keim, H.J., Weber, M.A., Sealey, J.E., and Laragh, J.H., Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme, N. Engl. J. Med., 206, 641, 1977.

    Google Scholar 

  69. Krieger, E.M., Salgado, H.C., Assan, C.J., Greene, L.J., and Ferreira, S.H., Potential screening test for detection of overactivity of the renin-angiotensin system, Lancet, 1, 269, 1971.

    PubMed  CAS  Google Scholar 

  70. Cushman, D.W., Cheung, H.S., Sabo, E.F., and Ondetti, M.A., Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids, Biochemistry, 16, 5484, 1977.

    PubMed  CAS  Google Scholar 

  71. Rubin, B., O’Keefe, E.H., Kotler, D.O., DeMaio, D.A., and Cushman, D.W., Use of excised guinea pig ileum as a predictive test for inhibitors in vivo of angiotensin-converting enzyme (ACE), Fed. Proc., 34, 770, 1975.

    Google Scholar 

  72. Rubin, B., Laffan, R.J., Kotler, D.G., O’Keefe, E.H., DeMaio, D.A., and Goldberg, M.E., SQ 14,225 (D-3-mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin-converting enzyme, J. Pharmacol. Exp. Ther. 204, 271, 1978.

    PubMed  CAS  Google Scholar 

  73. Rubin, B., Antonaccio, M.J., and Horovitz, Z.P., captopril (SQ 14,225) (D-3-mercapto-2-methylpropanoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent, Progr. Cardiovasc. Dis., 21, 183, 1978.

    CAS  Google Scholar 

  74. Harris, D.N., Heran, C.L., Goldenberg, H.J., High, J.P., Laffan, R.J., Rubin, B., Antonaccio, M.J., and Goldberg, M.E., Effects of SQ 14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs, Eur. J. Pharmacol., 51, 345, 1978.

    PubMed  CAS  Google Scholar 

  75. Murthy, V.S., Waldron, T.L., Goldberg, M.E., and Vollmer, R.R., Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits, Eur. J. Pharmacol 46, 207, 1977.

    PubMed  CAS  Google Scholar 

  76. Murthy, V.S., Waldron, T.L., and Goldberg, M.E., The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14,225 in conscious rabbits, Circu. Res., 43, 1–40, 1978.

    Google Scholar 

  77. Rubin, B., Duchin, K.L., and Antonaccio, M.J., Effects of chronic captopril (C) on renal function and vascular reactivity in conscious Wistar-Kyoto (WKY) rats, Fed. Proc, 38, 851, 1979.

    Google Scholar 

  78. Murthy, V.S., Waldron, T.L., and Goldberg, M.E., Inhibition of angiotensin converting enzyme by SQ 14,225 in anesthetized dogs: hemodynamic and renal vascular effects, Proc. Soc. Exp. Biol. Med., 157, 121, 1978.

    PubMed  CAS  Google Scholar 

  79. Vollmer, R.R. and Boccagno, J.A., Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats, Eur. J. Pharmacol., 45, 117, 1977.

    PubMed  CAS  Google Scholar 

  80. Ferguson, R.K., Brunner, H.R., Turini, G.A., Gavras, H., and McKinstry, D.N., A specific orally active inhibitor of angiotensin-converting enzyme in man, Lancet, 1, 775, 1977.

    PubMed  CAS  Google Scholar 

  81. Bing, J. and Poulsen, K., Time course of changes in plasma renin after blockade of the renin system, Acta Path. Microbiol, scand., Sect. A, 83, 454, 1975.

    CAS  Google Scholar 

  82. Haber, E., Sancho, J., Re, R., Burton, J., and Barger, A.C., The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal man, Clin. Sci. Mol. Med., 48, 495, 1975.

    Google Scholar 

  83. Samuels, A.I., Miller, Jr.,E.D., Fray, J.C.S., Haber, E.,and Barger, A.C.,Renin-angiotensin antagonists and the regulation of blood pressure, Fed. Proc, 35, 2512, 1976.

    PubMed  CAS  Google Scholar 

  84. Thurston, H. and Laragh, J.H., Prior receptor occupancy as a determinant of the pressor activity of infused angiotensin II in the rat, Circ. Res., 36, 113, 1975.

    PubMed  CAS  Google Scholar 

  85. Laffan, R.J., Goldberg, M.E., High, J.P., Schaeffer, T. R., Waugh, M.H., and Rubin, B., Antihypertensive activity in rats of SQ 14,225, an orally active inhibitor of angiotensin converting enzyme, J. Pharmacol. Exp. Ther., 204, 281, 1978.

    PubMed  CAS  Google Scholar 

  86. Bengis, R.G., Coleman, T.G., Young, D.B., and McCaa, R.E., Long-term blockade of angiotensin formation in various normotensive and hypertensive rat models using converting enzyme inhibitor (SQ 14,225), Circ. Res., 43 (Suppl. I),45, 1978.

    Google Scholar 

  87. Jaeger, P., Ferguson, R. K., Brunner, H.R., Kirchertz, R., and Gavras, H., Mechanism of blood pressure reduction by teprotide (SQ 20,881) in rats, Kidney Int., 13, 289, 1978.

    PubMed  CAS  Google Scholar 

  88. Vollmer, R.R., Boccagno, J.A., Harris, D.N., and Murthy, V.S., Hypotension induced by inhibition of angiotensin-converting enzyme in pentobarbital-anesthetized dogs, Eur. J. Pharmacol., 51, 39, 1978.

    PubMed  CAS  Google Scholar 

  89. McCaa, R.E., Hall, J.E.,and McCaa, C.S., The effects of angiotensin I-con-verting enzyme inhibitors on arterial blood pressure and urinary sodium excretion. Role of the renin-angiotensin and kallikrein-kinin systems, Circ. Res., 43 (Suppl. I), 32, 1978.

    CAS  Google Scholar 

  90. McCaa, R.E., McCaa, C.S., Bengis, R.G., and Guyton, A.C., Role of aldosterone in experimental hypertension, J. Endocrinol., 81, 69P, 1979.

    Google Scholar 

  91. Antonaccio, M.J., Rubin, B., Horovitz, Z.P., Mackaness, G., and Panasevich, R., Long-term efficacy of captopril (SQ 14,225) in 2-kidney renal hypertensive rats. Clin. Exp. Hypertension, 1, 505, 1979.

    CAS  Google Scholar 

  92. Brown, T.C, Davis, J.O., Olichney, M.J., and Johnston, C.I., Relation of plasma renin to sodium balance and arterial pressure in experimental renal hypertension, Circ. Res., 18, 475, 1966.

    PubMed  CAS  Google Scholar 

  93. Gavras, H., Oliver, J.A.,and Cannon, P.J., Interrelations of renin, angioten sin II, and sodium in hypertension and renal failure, Annu. Rev. Med., 27, 485, 1976.

    PubMed  CAS  Google Scholar 

  94. Mikoche, L.W., Miksche, U., and Gross, F., Effect of sodium restriction on renal hypertension and on renin activity in the rat, Circ. Res., 27, 973, 1970.

    Google Scholar 

  95. Rubin, B., Antonaccio, M.J., Goldberg, M.E., Harris, D.M., Itkin, I.G., Horovitz, Z.P., Panasevich, R.E., and Laffan, R.J., Chronic antihyperten sive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor in conscious 2-kidney renal hypertensive rats, Eur. J. Pharmacol., 51, 377, 1978.

    PubMed  CAS  Google Scholar 

  96. Douglas, J.R., Jr., Johnson, E.M., Jr., Heist, J.F., Marshall, G.R., and Needleman, P., Is the peripheral sympathoadrenal nervous system necessary for renal hypertension?, J. Pharmacol. Exp. Ther., 196, 35, 1976.

    PubMed  CAS  Google Scholar 

  97. Thurston, H. and Swales, J.D., Blood pressure response of nephrectomized hypertensive rats to converting enzyme inhibition: Evidence for persistent vascular renin activity, Clin. Sci. Mol. Med., 52, 299, 1977.

    PubMed  CAS  Google Scholar 

  98. Riegger, A.J.G., Lever, A.F., Millar, J.A., Morton, J.J.,and Slack, B., Correction of renal hypertension in rat by long term infusion of angiotensin inhibitors, Lancet, 2, 1317, 1977.

    PubMed  CAS  Google Scholar 

  99. Gavras, H., Brunner, H.R., Laragh, J.H., Gavras, I., and Vukovich, R. A., The use of angiotensin converting enzyme inhibitor in the. diagnosis and treatment of hypertension, Clin. Sci. Mol. Med., 48, 57S, 1975.

    Google Scholar 

  100. Sen, S., Smeby, R. R., Bumpus, F.M., and Turcotte, R.G., Role of renin-angiotensin system in chronic renal hypertensive rats, Hypertension, 1, 427, 1979.

    PubMed  CAS  Google Scholar 

  101. Freeman, R.H., Davis, J.O., Watkins, B.E., Stephens, G.A., and DeForrest, J.M., Effects of continuous converting enzyme blockade on renovascular hypertension in the rat, Am. J. Physiol., 236, F21, 1979.

    PubMed  CAS  Google Scholar 

  102. Watkins, B.E., Davis, J.O., Freeman, R.H., Stephens, G.A.,and DeForrest, J.M. Effects of oral converting enzyme inhibitor (SQ 14,225) on one-kidney hypertension in the dog, Proc. Soc. Exp. Biol. Med., 157, 245, 1978.

    PubMed  CAS  Google Scholar 

  103. Watkins, B.E., Davis, J.O., Freeman, R.H., DeForrest, J.M.,and Stephens, G.A., Continuous angiotensin II blockade throughout the acute phase of one-kidney hypertension in the dog, Circ. Res., 42, 813, 1978.

    PubMed  CAS  Google Scholar 

  104. Miller, E.D., Jr., Samuals, A.I., Haber, E., and Barger, A.C., Inhibition of angiotensin conversion in experimental renovascular hypertension, Science, 177, 1108, 1972.

    PubMed  CAS  Google Scholar 

  105. Ayers, C.R., Vaughan, E.D., Jr., Yancey, M.R., Bing, K.T., Johnson, C.C., and Morton, C, Effect of l-sarcosine-8-alanine angiotensin II and converting enzyme inhibitor on renin release in dog acute renovascular hypertension, Circ. Res., 34, 127, 1974.

    Google Scholar 

  106. Muirhead, E.E., Brooks, B.,and Arora, K.K., Prevention of malignant hypertension by the synthetic peptide SQ 20,881, Lab. Invest., 30, 129, 1974.

    CAS  Google Scholar 

  107. Svendsen, U.G., Effects of the nonapeptide (SQ 20,881) on the blood pressure of conscious normotensive and chronic hypertensive mice, Acta Path. Microbiol. Scand., Sect. A, 85, 942, 1977.

    CAS  Google Scholar 

  108. Watanabe, T.X. and Sokabe, H., Acute vasodepressor effect of D-3-mercapto-2-methyl-propanoyl-L-proline (SQ 14,225) in the stroke-prone substrain of spontaneously hypertensive rats (SHRSP), Jap. J. Pharmacol., 29, 133, 1979.

    PubMed  CAS  Google Scholar 

  109. Antonaccio, M.J., Rubin, B., Horovitz, Z.P., Laffan, R.J., Goldberg, M.E., Harris, D.N., and Zaidi, I. Effects of chronic treatment with Captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats, Jap. J. Pharmacol., 29, 285, 1979.

    PubMed  CAS  Google Scholar 

  110. Ferrone, R.A. and Antonaccio, M.J., Prevention of the development of spontaneous hypertension in rats by captopril (SQ 14,225), Eur. J. Pharmacol., In press.

    Google Scholar 

  111. Douglas, B.H., Langford, H.C., and McCaa, R.E., Response of mineralocorti-coid hypertensive animals to an angiotensin I converting enzyme inhibitor, Proc. Soc. Exp. Biol. Med., 161, 86, 1979.

    PubMed  CAS  Google Scholar 

  112. Atlas, S.A., Case, D.B., Sealey, J.E., McKinstry, D.N., and Laragh, J.H., Blunted aldosterone secretion, natriuresis and potassium retention during chronic aldosterone blockade in hypertensive patients, Clin. Res., 26, 361A, 1978.

    Google Scholar 

  113. Atlas, S.A., Case, D.B. Sealey, J.E., Sullivan, P.M., and Laragh, J.H., Involvement of the renin-angiotensin-aldosterone axis in the antihypertensive action of captopril (SQ 14,225), Circulation, 57/78 (Suppl. II), 11–143, 1978.

    Google Scholar 

  114. Case, D.B., Atlas, S.A., Laragh, J.H., Sealey, J.E., Sullivan, P.A., and McKinistry, D.N., Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, Captopril) in hypertensive patients, Prog. Cardiovasc. Dis., 21, 195, 1978.

    PubMed  CAS  Google Scholar 

  115. Atlas, S.A., Case, D.B., Sealey, J.E., Laragh, J.H., and McKinstry, D.N., Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis, Hypertension, 1, 274, 1979.

    PubMed  CAS  Google Scholar 

  116. Cody, R.J.,Jr., Tarazi, R.C., Bravo, E.L., and Fouad, F.M., Hemodynamics of orally-active converting enzyme inhibitor (SQ 14,225) in hypertensive patients. Clin. Sci. Mol. Med., 55, 453, 1978.

    PubMed  Google Scholar 

  117. Brunner, H. R., Gavras, H., Waeber, B., Kershaw, G.R., Turini, G.A., Vuko-vich, R.A., and McKinstry, D.N., Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients, Ann. Intern. Med., 90, 19, 1979.

    PubMed  CAS  Google Scholar 

  118. Brunner, H.R., Gavras, H., Turini, G.A., Waeber, B., and Wauters, J.P., Long-term angiotensin blockade in hypertensive patients with chronic renal failure Clin. Res., 26, 459A, 1978.

    Google Scholar 

  119. Brunner, H.R., Waeber, B., Wauters, J.P., Turini, G., McKinstry, D., and Gavras, H., Inappropriate renin secretion unmasked by captopril (SQ 14,225) in hypertension of chronic renal failure, Lancet, 2, 704, 1978.

    PubMed  CAS  Google Scholar 

  120. Baker, K.M. Vaughn, E.D., Jr., Johns, D.W., Ayers, C.R., and Carey, R.M., Antihypertensive effects of angiotensin blockade: SQ 14,225 versus P113, Clin. Res., 26, 779A, 1978.

    Google Scholar 

  121. Bravo, E. L. and Tarazi, R.C., Converting enzyme inhibition with an orally active compound in hypertensive man, Hypertension, 1, 39, 1979.

    PubMed  CAS  Google Scholar 

  122. Gavras, H., Brunner, H.R., Turini, G.A., Kershaw, G.R., Tifft, C.P., Cutte-lod, S., Gavras, I., Vukovich, R.A., and McKinstry, D.N., Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14,225 in man, N. Engl. J. Med., 298, 991, 1978.

    PubMed  CAS  Google Scholar 

  123. Sullivan, J.M., Ginsburg, B.A., Ratts, T.E., Johnson, J.G., Barton, B.A., Kraus, D.H., McKinstry, D.N., and Muirhead, E.E., Hemodynamic and antihypertensive effects of Captopril, an orally active angiotensin converting enzyme inhibitor, Hypertension, 1, 397, 1979.

    PubMed  CAS  Google Scholar 

  124. Favre, L., Frazer, M., McKinstry, D.N., and Hollifield, J.W., Chronic antihypertensive therapy with an oral converting-enzyme inhibitor (CEI), Circulation, 57/58 (Suppl. II), 1–57, 1978.

    Google Scholar 

  125. McKinstry, D.N., Willard, D.A., and Vukovich, R.A., Antihypertensive and hormonal effects of the converting enzyme inhibitor, Captopril, alone or combined with hydrochlorothiazide, Clin. Pharmacol. Ther., 25, 237, 1979.

    Google Scholar 

  126. Ferrone, R.A. and Heran, C.L., Hemodynamic effects of SQ 14,225 and guanethi-dine in spontaneously hypertensive rats. Circulation, 57/58 (Suppl. II), 11–144, 1978.

    Google Scholar 

  127. Muirhead, E. E., Prewitt, R. L., Jr., Brooks, B., and Brosius, W. L., Jr., Antihypertensive action of the orally active converting enzyme inhibitor (SQ 14,225) in spontaneously hypertensive rats, Circ. Res. (Suppl. I), 43: 153, 1978.

    Google Scholar 

  128. Duchin, K. L. and Steinbacher, T.E., Effects of captopril (SQ 14,225) on renal function in the dog. Kidney Int., 14, 693, 1978.

    Google Scholar 

  129. Ondetti, M.A. and Cushman, D.W., Angiotensin-Converting Enzyme Inhibitors, in The Biochemical Regulation of Blood Pressure. Soffer, R.L., Ed., John Wiley and Sons, New York, In press.

    Google Scholar 

  130. Antonaccio, M.J., Harris, D., Goldenberg, H., High, J.P.,and Rubin, B., The effects of Captopril, propranolol, and indomethacin on blood pressure and plasma renin activity in spontaneously hypertensive and normotensive rats, Proc. Soc. Exp. Biol. Med., In press.

    Google Scholar 

  131. Brunner, H.R., Gavras, H.,and Laragh, J.H., Hypertension in man. Exposure of the renin and sodium components using angiotensin II blockade. Circ Res. 34/35 (Suppl. I), 135, 1974.

    Google Scholar 

  132. Pettinger, W.A. and Mitchell, H.C., Renin release, saralasin, and the vasodilator-beta blocker drug interaction in man, N. Engl. J. Med., 292, 1214, 1975.

    CAS  Google Scholar 

  133. Atkinson, A.B., Brown, J.J., Lever, A.F., Morton, J.J., Frazer, R., and Robertson, J.I.S., Changes in plasma angiotensin II during captopril therapy in renal hypertension and intractable essential hypertension. Proceedings of the 6th Scientific Meeting of the International Society on Hypertension, Göteborg, June 11-13, p. 121, 1979.

    Google Scholar 

  134. Matthews, 6., McGrath, B.,and Johnston, C, Hormonal changes with long-term converting enzyme inhibition by captopril in essential hypertension, Proceedings of the 6th Scientific Meeting of the International Society on Hypertension, Göteborg, June 11-13, p. 156, 1979.

    Google Scholar 

  135. Millar, J.A., and Johnston, C.I., The effect of captopril (SQ 14,225) on circulating levels and clearance of angiotensin I and bradykinin in man, dog, and rabbit, Proceedings of the 6th Scientific Meeting of the International Society on Hypertension, Goteborg, June 11-13, p. 157, 1979.

    Google Scholar 

  136. Keim, H.J., Bindel, G., Distler, A., Fleckenstein, P.,and Cordes, U., Long-term treatment of essential hypertension (EH) with the oral converting enzyme inhibitor SQ 14,225, Proceedings of the 6th Scientific Meeting of the International Society on Hypertension, Goteborg, June 11-13, p. 144, 1979.

    Google Scholar 

  137. McKinstry, D.N., Singhvi, S.M., Kripalani, K.J., Dreyfuss, J., Willard, D.A., and Vukovich, R.A., Disposition and cardiovascular-endocrine effects of an orally active angiotensin-converting enzyme inhibitor, SQ 14,225, in normal subjects, Clin. Pharmacol. Ther., 23, 121, 1978.

    Google Scholar 

  138. Crofton, J.T., Share, L.,and Horovitz, Z.P., The effect of SQ 14,225 on systolic blood pressure and urinary excretion of vasopressin in the developing SH rat. Hypertension, 1, 462, 1979.

    PubMed  CAS  Google Scholar 

  139. Johnson, J.A. and Davis, J.O., Effects of a specific competitive antagonist of angiotensin II on arterial pressure and adrenal steroid secretion in the dog, Circ. Res., 32 (Suppl. I), 1159, 1973.

    Google Scholar 

  140. Watkins, L.J., Burton, J.A., Huber, E., Cant, T.R., Smith, F.W., and Bar-ger, A.C., The renin-angiotensin system in congestive failure in conscious dogs, J. Clin. Invest., 57, 1606, 1976.

    PubMed  CAS  Google Scholar 

  141. Freeman, R.H., Davis, J.O., Williams, G.M., DeForrest, J.M., Seymour, A.A., and Rowe, B.P., Effects of the oral converting enzyme inhibitor, SQ 14,225, in a model of low cardiac output in dogs, Circ. Res., 45, 540, 1979.

    PubMed  CAS  Google Scholar 

  142. Williams, G.M., David, J.O., Freeman, R.H., DeForrest, J.M., Seymour, A.A., and Rowe, B.P. Effects of the oral converting enzyme inhibitor, SQ 14,225, in experimental high output failure, Am. J. Physiol., 236, F541, 1979.

    PubMed  CAS  Google Scholar 

  143. Adler, R., Chatterjee, K., Ports, T., Hiramatsu, B.,and Parmley, W., Beneficial hemodynamic effects of angiotensin converting enzyme inhibitor in chronic refractory heart failure, Am. J. Cardiol., 43, 404, 1979.

    Google Scholar 

  144. Davis, R., Ribner, H.S., Keung, E., Sonnenblick, E.H., and LeJemtel, T.H., Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme, N. Engl. J. Med., 301, 117, 1979.

    PubMed  CAS  Google Scholar 

  145. Turini, G.A., Gribic, M., Brunner, H.R., Waeber, B.,and Gavras, H., Improvement of chronic congestive heart failure by oral captopril, Lancet, 1, 1213, 1979.

    PubMed  CAS  Google Scholar 

  146. Mason, D.T., Awan, N.A., Hennanovich, J. and Joye, O.A., Oral captopril in congestive heart failure: efficacy by cardiac catherization, forearm plethysmography, nuclear scintigraphy, echography, treadmill exercise symptoms, Circulation, 59/60 (Suppl. II), 230, 1979.

    Google Scholar 

  147. Levine, T.B., Carlyle, P.F., Gross, K.A., Franciosa, J.A. and Cohn, J.A., Hemodynamic and clinical response to captopril in congestive heart failure, Circulation, 59/60 (Suppl. II), 39, 1979.

    Google Scholar 

  148. Halperin, J.L., Creager, M.A., Faxon, D.P., Gavras, H, and Ryan, T.J., Chronic oral angiotensin inhibition for the treatment of refractory heart failure, Circulation, 59/60 (Suppl. II), 39, 1979.

    Google Scholar 

  149. Fouad, F.M., Cerino, J.M., Tarazi, R.C. and Bravo, E.L., Converting enzyme inhibition (CEI) in normotensive heart failure (HF): long term hemodynamic and humoral effects, Circulation, 59/60 (Suppl. II), 130, 1979.

    Google Scholar 

  150. Fouad, F.M., Cerino, J.M., Tarazi, R.C. and Bravo, E.L., Oral converting enzyme inhibitor in resistant heart failure, Clin. Res., 27, 673A, 1979.

    Google Scholar 

  151. Trache, G.J. and Lefer, A.M., Beneficial action of a new angiotensin-con-verting enzyme inhibitor (SQ 14,225) in hemorrhagic shock in cats, Cire. Res., 43, 576, 1978.

    Google Scholar 

  152. Hollenberg, N.K., Williams, G.H., Adams, D.F., Moore, T., Brown, C, Borucki, L.J Leung, F., Booli, S., Solomon, H.S., Passau, D. and Dluhy, R., Pharmacological interruption of the renin-angiotensin system, Medicine, 58, 115, 1979.

    PubMed  CAS  Google Scholar 

  153. Carretero, O.A. and Gulati, O.P., Effects of angiotensin antagonist in rats with acute, subacute, and chronic two-kidney renal hypertension, J. Lab. Clin. Med., 91, 264, 1978.

    PubMed  CAS  Google Scholar 

  154. Koletsky, S., Rivera-Velez, J.M., Marsh, D.G., and Pritchard, W.H., Relation of renal arterial pressure to activity of renin-angiotensin system in renal hypertension, Proc. Soc. Exp. Biol. Med., 125, 96, 1967.

    PubMed  CAS  Google Scholar 

  155. Koletsky, S. and Rivera-Velez, J.M., Factors determining the success or failure of nephrectomy in experimental renal hypertension, J. Lab. Clin. Med., 76., 54, 1970.

    PubMed  CAS  Google Scholar 

  156. Shiono, K. and Sokabe, H., Renin-angiotensin system in spontaneously hypertensive rats, Am. J. Physiol., 231, 1295, 1976.

    PubMed  CAS  Google Scholar 

  157. Pals, D.T., Masucci, F.D., Denning, G.S., Jr., Sipos, F., and Fessier, D.C., Role of the pressor action of angiotensin II in experimental hypertension, Circ. Res., 29, 673, 1971.

    PubMed  CAS  Google Scholar 

  158. Miyazaki, M. and Yamamoto, K., Synthetic phosphatidyl-ethanolamines as renin inhibitors, Proc. Soc. Exp. Biol. Med., 155, 468, 1977.

    PubMed  CAS  Google Scholar 

  159. Horovitz, Z.P., Pharmacology and mechanism of action of inhibitors of the angiotensin converting enzyme in Pharmacology and Clinical Use of Angiotensin I Converting Enzyme Inhibitors, Drug Development and Evaluation, voll 4. Gross, F. and Liedtke, R.K., Eds., Gustav Fischer Verlag, Stuttgart, 1980, p. 9–14.

    Google Scholar 

  160. Ganten, D., Hutchinson, J.S., Schelling, P., Ganten, U.,and Fischer, H., The iso-renin angiotensin systems in extrarenal tissue, Clin. Exp. Pharmacol. Physiol., 3, 103, 1976.

    PubMed  CAS  Google Scholar 

  161. Swales, J.D., Arterial wall or plasma renin in hypertension, Clin. Sci., 56, 293, 1979.

    PubMed  CAS  Google Scholar 

  162. Sen, S., Smeby, R. R., and Bumpus, F.M., Renin in rats with spontaneous hypertension, Circ. Res., 31, 876, 1972.

    PubMed  CAS  Google Scholar 

  163. Asaad, M.M. and Antonaccio, M.J., The effects of captopril (SQ 14,225) on vascular tissue renin in spontaneously hypertensive (SHR) and WKY-normotensive (NTR) rats: Relationship to systolic blood pressure (SBP) and plasma renin activity (PRA), Pharmacologist, 21, 212, 1979.

    Google Scholar 

  164. Aoki, K., Experimental studies on the relationship between endocrine organs and hypertension in spontaneously hypertensive rats. III. Role of the endocrine organs and hormones, Jap. Heart J., 5, 57, 1964.

    Google Scholar 

  165. Okamoto, K. and Aoki, K., Development of a strain of spontaneously hypertensive rats, Jap. Cire. J., 27, 282, 1963.

    CAS  Google Scholar 

  166. Swales, J.D., Antagonists, inhibitors and antisera in the evaluation of vascular renin activity. In: Progress in Biochemical Pharmacology. Vol. 12: Drugs Affecting the Renin-Angiotensin-Aldosterone System. Use of Angiotensin Inhibitors, edited by G.S. Stokes and K.D.G. Edwards, pp. 98–113, S. Karger, New York.

    Google Scholar 

  167. Antonaccio, M.J., Rubin, B.,and Horovitz, Z.P., Effects of captopril in animal models of hypertension, Clin. Exp. Hypertension, In press.

    Google Scholar 

  168. Margolius, H.S., Geller, R., DeJong, W., Pisano, J.J., and Sjoerdsma, A., Altered urinary kallikrein excretion in rats with hypertension, Circ. Res. 30, 358, 1972.

    PubMed  CAS  Google Scholar 

  169. Waeber, B., Brunner, H.R., Turini, G.A., Curtet, N., and Gavras, H., Blood pressure control by captopril despite intermittent normalization of angiotensin converting enzyme activity, Clin. Res., 27, 319A, 1979.

    Google Scholar 

  170. McCarthy, D.A., Potter, D.E., and Nicolaides, E.D., An in vivo estimation of of the potencies and half-lives of synthetic bradykinin and kallidin, J. Pharmacol. Exp. Ther., 148, 117, 1965.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. Antonaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z. P. Horovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Eden Press Incorporated

About this chapter

Cite this chapter

Rubin, B., Antonaccio, M.J., Horovitz, Z.P. (1980). The Renin-Angiotensin System, Converting Enzyme Inhibition, and Antihypertensive Therapy. In: Progress in Hormone Biochemistry and Pharmacology. Progress in Hormone Biochemistry and Pharmacology, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-7712-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-7712-2_1

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-011-7714-6

  • Online ISBN: 978-94-011-7712-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation